Pharmacyte Biotech Inc (OTCMKTS:PMCB) Fails To Move Up (NPHC, GBLX)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) highlighted major goals that need to be met in order to begin Phase 2b study for pancreatic cancer treatment. This study will examine the safety and efficacy of designed pancreatic cancer treatment. The therapy is a well-planned combination of microcapsules comprising genetically modified live cells and ifosfamide dosage. Pharmacyte revealed that […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Updates On Interim Audit Completion Of cGMP Facility

Pharmacyte Biotech Inc (OTCMKTS:PMCB) stated that it has completed the interim audit of cGMP facility. The company will acquire the cell-in-a-box capsules for the clinical trials from the same facility. Austrianova’s Chief Technical Officer, Professor Walter H. Günzburg, stated that they are pleased to report that there were no major issues during the inspection process. […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) And Growblox Sciences Inc (OTCMKTS:GBLX) Trades In A Narrow Range

Pharmacyte Biotech Inc (OTCMKTS:PMCB) declined 0.52% and closed at $0.0959 in last trading session. The biotech firm is still in clinical stage and it is working to develop targeted therapies to treat diabetes and cancer based on Cell-in-a-Box® technology. Recently, the COO of Pharmacyte, Dr. Gerald W. Crabtree, Ph.D. highlighted company’s development plans in an […]